Method of Assessing Activity of Recombinant Antigen Receptors

Juno, Inc.

A patent family: one line of work, grouped by real continuity rather than by a technology label inferred from titles. 2 of these applications claim priority to application PCT/US2018/058781, filed Nov 1, 2018. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.

Patent	Title	Holder	Status	Expires	Time remaining	Confidence
US 12,703,734	Method of Assessing Activity of Recombinant Antigen Receptors Juno Therapeutics, Inc. In force Term ends Apr 17, 2039 · High confidence	Juno Therapeutics, Inc.	In force	Term ends Apr 17, 2039	Term ends Apr 17, 2039	High confidence
US 11,851,679	Method of Assessing Activity of Recombinant Antigen Receptors Juno Therapeutics, Inc. In force Term ends Sep 17, 2040 · High confidence	Juno Therapeutics, Inc.	In force	Term ends Sep 17, 2040	Term ends Sep 17, 2040	High confidence

2 of 2 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.

Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know

Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.